We send the latest information from SMC Laboratories.
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. W…
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection…
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the …
We are excited to share with you an update about a newly established positive control – an ALK5 inhibito…
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b…
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first…
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detai…
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a …
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT …
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-10…